GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Beneish M-Score

Firebrick Pharma (ASX:FRE) Beneish M-Score : -5.63 (As of Jun. 23, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -5.63 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Firebrick Pharma's Beneish M-Score or its related term are showing as below:

ASX:FRE' s Beneish M-Score Range Over the Past 10 Years
Min: -5.63   Med: -5.63   Max: -5.63
Current: -5.63

During the past 3 years, the highest Beneish M-Score of Firebrick Pharma was -5.63. The lowest was -5.63. And the median was -5.63.


Firebrick Pharma Beneish M-Score Historical Data

The historical data trend for Firebrick Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Beneish M-Score Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23
Beneish M-Score
- - -5.63

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Beneish M-Score - - -5.63 -

Competitive Comparison of Firebrick Pharma's Beneish M-Score

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Beneish M-Score falls into.



Firebrick Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Firebrick Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5065+0.528 * 1+0.404 * 2.9272+0.892 * 0.25+0.115 * 0.6286
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.1846+4.679 * -0.349095-0.327 * 3.2915
=-5.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was A$0.14 Mil.
Revenue was A$0.00 Mil.
Gross Profit was A$0.00 Mil.
Total Current Assets was A$2.59 Mil.
Total Assets was A$2.98 Mil.
Property, Plant and Equipment(Net PPE) was A$0.03 Mil.
Depreciation, Depletion and Amortization(DDA) was A$0.01 Mil.
Selling, General, & Admin. Expense(SGA) was A$0.66 Mil.
Total Current Liabilities was A$0.51 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.
Net Income was A$-6.80 Mil.
Gross Profit was A$0.02 Mil.
Cash Flow from Operations was A$-5.78 Mil.
Total Receivables was A$1.08 Mil.
Revenue was A$0.00 Mil.
Gross Profit was A$0.00 Mil.
Total Current Assets was A$8.33 Mil.
Total Assets was A$8.73 Mil.
Property, Plant and Equipment(Net PPE) was A$0.04 Mil.
Depreciation, Depletion and Amortization(DDA) was A$0.01 Mil.
Selling, General, & Admin. Expense(SGA) was A$0.83 Mil.
Total Current Liabilities was A$0.45 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.137 / 0.001) / (1.082 / 0.004)
=137 / 270.5
=0.5065

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.004 / 0.004) / (0.001 / 0.001)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.589 + 0.034) / 2.982) / (1 - (8.328 + 0.042) / 8.729)
=0.120389 / 0.041127
=2.9272

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.001 / 0.004
=0.25

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.007 / (0.007 + 0.042)) / (0.01 / (0.01 + 0.034))
=0.142857 / 0.227273
=0.6286

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0.66 / 0.001) / (0.829 / 0.004)
=660 / 207.25
=3.1846

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 0.506) / 2.982) / ((0 + 0.45) / 8.729)
=0.169685 / 0.051552
=3.2915

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-6.802 - 0.022 - -5.783) / 2.982
=-0.349095

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Firebrick Pharma has a M-score of -5.63 suggests that the company is unlikely to be a manipulator.


Firebrick Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma (ASX:FRE) Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines